134 related articles for article (PubMed ID: 36394153)
1. PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.
Guo C; Liao KH; Li M; Wang IM; Shaik N; Yin D
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1619-1625. PubMed ID: 36394153
[TBL] [Abstract][Full Text] [Related]
2. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations.
Rodon J; Rodriguez E; Maitland ML; Tsai FY; Socinski MA; Berlin JD; Thomas JS; Al Baghdadi T; Wang IM; Guo C; Golmakani M; Clark LN; Gazdoiu M; Li M; Tolcher AW
ESMO Open; 2024 Apr; 9(4):102961. PubMed ID: 38640748
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
4. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Bender BC; Schaedeli-Stark F; Koch R; Joshi A; Chu YW; Rugo H; Krop IE; Girish S; Friberg LE; Gupta M
Cancer Chemother Pharmacol; 2012 Oct; 70(4):591-601. PubMed ID: 22886072
[TBL] [Abstract][Full Text] [Related]
5. Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.
Ji Y; Huang PH; Woolfenden S; Myers A
Clin Transl Sci; 2022 Jul; 15(7):1713-1722. PubMed ID: 35620969
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
Nomoto M; Ferry J; Hussein Z
J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
[TBL] [Abstract][Full Text] [Related]
8. Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Chalret du Rieu Q; Fouliard S; Jacquet-Bescond A; Robert R; Kloos I; Depil S; Chatelut E; Chenel M
Pharm Res; 2013 Oct; 30(10):2640-53. PubMed ID: 23737346
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
[TBL] [Abstract][Full Text] [Related]
10. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
[TBL] [Abstract][Full Text] [Related]
11. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Bauer S; Demetri GD; Halilovic E; Dummer R; Meille C; Tan DSW; Guerreiro N; Jullion A; Ferretti S; Jeay S; Van Bree L; Hourcade-Potelleret F; Wuerthner JU; Fabre C; Cassier PA
Br J Cancer; 2021 Aug; 125(5):687-698. PubMed ID: 34140638
[TBL] [Abstract][Full Text] [Related]
13. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M
Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Banerji U; van Doorn L; Papadatos-Pastos D; Kristeleit R; Debnam P; Tall M; Stewart A; Raynaud F; Garrett MD; Toal M; Hooftman L; De Bono JS; Verweij J; Eskens FA
Clin Cancer Res; 2012 May; 18(9):2687-94. PubMed ID: 22553374
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Vieito M; Moreno V; Spreafico A; Brana I; Wang JS; Preis M; Hernández T; Genta S; Hansen AR; Doger B; Galvao V; Lenox L; Brown RJ; Kalota A; Mehta J; Pastore F; Patel B; Mistry P; Gu J; Lauring J; Patel MR
Clin Cancer Res; 2023 Sep; 29(18):3592-3602. PubMed ID: 37491846
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Krishnatry AS; Hanze E; Bergsma T; Dhar A; Prohn M; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):556-568. PubMed ID: 34648693
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Fernández-Teruel C; Lubomirov R; Fudio S
J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
[TBL] [Abstract][Full Text] [Related]
18. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
19. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
[TBL] [Abstract][Full Text] [Related]
20. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]